Senses Disorder TRIZ Cases

Transplanting gene-edited HSPCs restores corneal thickness and reduces cystine accumulation in hereditary eye disorders.

A filter matrix applicator delivers ocular medication via capillary absorption, reducing bioavailability loss from reflex tearing and spillage.

L-carnitine eye drops address dry eye syndrome by promoting cellular health and osmolarity regulation.

An ophthalmic injector employs a valve mechanism between the reservoir and cannula to prevent leakage while enabling precise injection control.

Synthetic peptide H-473 inhibits cancer cell growth and vascular proliferation through multi-target receptor interference.

Formula I compounds block lysophosphatidic acid receptor activity, resolving the lack of effective inhibitors for fibrosis and cancer.

Controlled phospholipid concentrations in a composite formulation reduce corneal opacity and intraocular pressure while maintaining therapeutic efficacy.

Novel imidazopyrazine compounds block IRE1α RNase activity to prevent apoptosis, resolving tissue damage risks in neurodegenerative and eye disease treatments.

Small molecule compounds correct defective protein folding and trafficking to restore anion transport function in cystic fibrosis treatment.

Sodium acetate storage extends adipose stem cell viability to 48 hours, countering ischemic damage from conventional tumescent solutions.

Magnetic nanoparticles transport siRNA across the blood labyrinthine barrier to target Hes1, solving delivery complexity while ensuring safety.

A florfenicol microemulsion formulation delivers sustained antibiotic levels via subcutaneous injection.

Chemical modifications to macrocyclic lactones improve water solubility and reduce toxicity while maintaining immunosuppressive potency.

A polymeric clotrimazole biofilm delivers sustained antifungal therapy via a flexible tympanic patch.

A drug delivery device uses a wicking material within a delivery window to modify API transport rates through capillary action.

A triazine derivative inhibits PI3 kinase and mTOR enzymes simultaneously.

Segmented duplexes with 2'-O-methyl substitutions prevent interferon activation and extend serum half-life without triggering immune responses.

Formula I quinonyl derivatives modulate cellular energy biomarkers to support mitochondrial function.

A thermoresponsive pharmaceutical composition increases viscosity at body temperature to enhance retention of recombinant adeno-associated virus vectors.

Quaternary salt compounds inhibit monocyte chemotaxis to reduce inflammatory responses while managing formulation complexity.

Screened mutated parvovirus structural proteins bind therapeutic antibodies to induce polyclonal immune responses, overcoming anti-idiotype limitations.

A petrolatum-based eye care composition disperses cationic biocides as nanodroplets in saline without added emulsifiers.

A quinolyl-substituted carboxylic acid compound inhibits AXL and VEGFR2 kinases through specific molecular binding.

Arginine salts convert unstable oils into crystalline solids, reducing metabolic degradation while maintaining potency.

Tri-phenyl compounds modulate telomerase activity via local quality principles, balancing extended cellular lifespan against somatic cancer risks.

Thiolated polyvinyl alcohol reacts with a thiol-reactive polymer to form an in situ gel that supports retinal healing without requiring surgical removal.

Selective TrkA kinase inhibitors block pain signaling pathways, avoiding opioid addiction and respiratory depression risks.

Intravitreal sirolimus reduces central subfield thickness to address persistent edema when anti-VEGF agents fail.

Direct condensation of unprotected primary amines with 4-chloroacetamido-4'-demethylepipodophyllotoxin reduces synthesis steps from 11 to 3 and doubles yield.

An ACTA2 inhibitor composition targets smooth muscle cells to restore pericyte distribution in the eye.

2-pyridine piperidine compounds activate soluble guanylate cyclase to enhance aqueous humor drainage.

Extended tPA administration enhances outflow facility and sustains intraocular pressure reduction without acute bleeding risks.

Adeno-associated viral vectors deliver human PRPF31 sequences to retinal pigment epithelial cells.

2-Alkoxy-3,4,5-trihydroxy-alkylamide-benzothiazepines improve bioavailability and solubility while maintaining potent anticancer activity.

Retinal inactivation with tetrodotoxin reverses amblyopia by resetting cortical plasticity thresholds to restore binocularity.

DII4 antagonists inhibit pathological neovascularization while promoting productive angiogenesis to improve tissue perfusion in ischemic injury.

Boron compounds inhibit pro-inflammatory cytokines and enhance anti-inflammatory activity to reduce side effects.

Humanized antibodies bind interleukin-12 and interleukin-23 to extend serum half-life and reduce immune reactions.

Monoclonal antibodies bind RGM A protein to neutralize inhibitory effects, promoting retinal nerve fiber layer degeneration treatment.

AAV-mediated FOXC1 overexpression inhibits corneal neovascularization caused by trauma or infection.

Suspension culture with thyroid hormone agonists suppresses ganglion cell differentiation in retinal tissue.

pH-dependent anti-C5 antibodies resolve dosing frequency issues by binding strongly at physiological pH while dissociating rapidly in acidic endosomes.

Novel solid form of plasma kallikrein inhibitor reduces hygroscopicity and anaphylactic risk while improving bioavailability.

Small molecule compounds counteract VEGF effects and endothelial tube formation, offering a cost-effective topical alternative to antibody therapies.

Tricyclic GPR40 agonists trigger glucose-dependent insulin secretion, eliminating hypoglycemia risks inherent in traditional secretagogues.

N-urea substituted amino acid derivatives modulate the formyl peptide receptor 2 to treat inflammatory disorders.